To investigate the changes and the reliability of multifocal electroretinogram (mfERG) after intravitreal triamcinolone acetonide (IVTA) injection in diffuse diabetic macular edema (DDME).
Methods
Twenty-four eyes with DDME were treated with an intravitreal injection of 4 mg of triamcinolone acetonide. Visual acuity (VA), central macular thickness (CMT), mfERG, and intraocular pressures (IOP) were evaluated in the preinjection period and the 15th day, third month, and sixth month after IVTA injection.
Results
Age and gender of the patients were not significantly correlated to logMAR VA (p=0.888 for age, p=0.192 for gender), CMT (p=0.282 for age, p=0.625 for gender), or P1/N1 amplitudes/implicit times in mfERG at baseline (p>0.05 for age and gender). The correlation between logMAR VA and CMT at baseline also was not significant (r=0.069, p=0.750). The VA increased significantly at the 15th day (p<0.001). The VA increase persisted until the third month and decreased to preinjection values at the sixth month (p=0.324). CMT decrease was significant at the 15th day (p=0.012) but insignificant at the third and sixth months (p=1.000 for both). Correlations between logMAR VA change/CMT change at the 15th day were not significant (r=–0.043, p=0.843). Moreover, the correlation of CMT change with P1/N1 amplitude/implicit time changes was not significant (p>0.05 for all).
Conclusions
The positive effect of IVTA injection in DDME is reversible until the sixth month. Monitoring of the improvement in visual function by mfERG is violated possibly by irreversible macular dysfunction due to long duration of macular edema and primary neurophysiologic effects of diabetes on the retina.
MossS.E., KleinR., KleinB.E.The incidence of vision loss in a diabetic population.Ophthalmology1988; 95: 1340–8.
2.
KleinR., KleinB.E., MossS.E., DavisM.D., DeMetsD.L.The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema.Ophthalmology1984; 91: 1464–74.
3.
Early Treatment Diabetic Retinopathy Study research group.Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1.Arch Ophthalmol1985; 103: 1796–806.
4.
SutterF.K., SimpsonJ.M., GilliesM.C.Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: 3-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial.Ophthalmology2004; 111: 2044–9.
5.
Bonini-FilhoM.A., JorgeR., BarbosaJ.C., CalucciD., CardilloJ.A., CostaR.A.Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial.Invest Ophthalmol Vis Sci2005; 46: 3845–9.
6.
MassinP., AudrenF., HaouchineB.. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial.Ophthalmology2004; 111: 218–24; discussion 224–5.
7.
WilsonC.A., BerkowitzB.A., SatoY., AndoN., HandaJ.T., de JuanE.Jr.. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation.Arch Ophthalmol1992; 110: 1155–9.
MachemerR., SugitaG., TanoY.Treatment of intraocular proliferations with intravitreal steroids.Trans Am Ophthalmol Soc1979; 77: 171–80.
10.
McCuenBW2nd, BesslerM., TanoY., ChandlerD., MachemerR.The lack of toxicity of intravitreally administered triamcinolone acetonide.Am J Ophthalmol1981; 91: 785–8.
11.
YoungS., LarkinG., BranleyM., LightmanS.Safety and efficacy of intravitreal triamcinolone for cystoid macular edema in uveitis.Clin Exp Ophthalmol2001; 29: 2–6.
12.
AntcliffR.J., SpaltonD.J., StanfordM.R., GrahamE.M., FfytcheT.J., MarshallJ.Intravitreal triamcinolone for uveitis cystoid macular edema: an optical coherence tomography study.Ophthalmology2001; 108: 765–72.
13.
MartidisA., DukerJ.S., PuliafitoC.A.Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy.Arch Ophthalmol2001; 119: 1380–3.
JonasJ.B., HaylerJ.K., SöfkerA., Panda-JonasS.Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone.J Glaucoma2001; 10: 284–7.
16.
JonasJ.B., HaylerJ.K., SöfkerA., Panda-JonasS.Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy.Am J Ophthalmol2001; 131: 468–71.
17.
JonasJ.B., HaylerJ.K., Panda-JonasS.Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy.Br J Ophthalmol2000; 84: 1064–7.
18.
TanoY., ChandlerD., MachemerR.Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide.Am J Ophthalmol1980; 90: 810–6.
19.
GreenbergP.B., MartidisA., RogersA.H., DukerJ.S., ReichelE.Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion.Br J Ophthalmol2002; 86: 247–8.
20.
ParkC.H., JaffeG.J., FekratS.Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion.Am J Ophthalmol2003; 136: 419–25.
SaraivaV.S., SallumJ.M., FarahM.E.Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide.Ophthalmic Surg Lasers Imaging2003; 34: 398–400.
JonasJ.B., SöfkerA.Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema.Am J Ophthalmol2001; 132: 425–7.
25.
JonasJ.B., KreissigI., SöfkerA., DegenringR.F.Intravitreal injection of triamcinolone for diffuse diabetic macular edema.Arch Ophthalmol2003; 121: 57–61.
26.
CiullaT.A., WalkerJ.D., FongD.S., CriswellM.H.Corticosteroids in posterior segment disease: an update on new delivery systems and new indications.Curr Opin Ophthalmol2004; 15: 211–20.
27.
LarssonJ., ZhuM., SutterF., GilliesM.C.Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone.Am J Ophthalmol2005; 139: 802–6.
28.
CringleS.J., YuD.Y., AlderV.A., SuE.N.Retinal blood flow by hydrogen clearance polarography in the streptozotocin-induced diabetic rat.Invest Ophthalmol Vis Sci1993; 34: 1716–21.
29.
AdlerV.A., YuD-Y, CrigleS.J., SuE.N.Changes in vitreal oxygen tension distribution in the streptozotocin diabetic rat.Diabetologia1991; 34: 469–76.
30.
GrunwaldJ.E., BruckerA.J., BraunsteinS.N.. Strict metabolic control and retinal blood flow in diabetes mellitus.Br J Ophthalmol1994; 78: 598–604.
31.
GrunwaldJ.E., RivaC.E., PetrigB.L.. Strict control of glycaemia: effects on blood flow in the large retinal vessels and in the macular microcirculation.Br J Ophthalmol1995; 79: 735–41.
LiskaV., DostalekM.Are contrast sensitivity functions impaired in insulin dependent diabetics without diabetic retinopathy?Acta Medica (Hradec Kralove)1999; 42: 133–8.
38.
KawasakiK., YonemuraK., YokogawaY., SaitoN., KawakitaS.Correlation between ERG oscillatory potential and psychophysical contrast sensitivity in diabetes.Doc Ophthalmol1986; 64: 209–15.
39.
ParisiV., UccioliL., MonticoneG., ParisiL., MenzingerG., BucciM.G.Visual evoked potentials after photostress in insulin-dependent diabetic patients with or without retinopathy.Graefes Arch Clin Exp Ophthalmol1994; 232: 193–8.
40.
JuenS., KieselbachG.F.Electrophysiological changes in juvenile diabetics without retinopathy.Arch Ophthalmol1990; 108: 372–5.
41.
BresnickG.H., PaltaM.Oscillatory potential amplitudes. Relation to severity of diabetic retinopathy.Arch Ophthalmol1987; 105: 929–33.
42.
BresnickG.H., PaltaM.Predicting progression to severe proliferative diabetic retinopathy.Arch Ophthalmol1987; 105: 810–14.
43.
FortuneB., SchneckM.E., AdamsA.J.Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy.Invest Ophthalmol Vis Sci1999; 40: 2638–51.
44.
HanY., BearseM.A.Jr., SchneckM.E., BarezS., JacobsenC.H., AdamsA.J.Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy.Invest Ophthalmol Vis Sci2004; 45: 948–54.
45.
BearseM.A.Jr., HanY., SchneckM.E., AdamsA.J.Retinal function in normal and diabetic eyes mapped with the slow flash multifocal electroretinogram.Invest Ophthalmol Vis Sci2004; 45: 296–304.
46.
Bronson-CastainK.W., BearseM.A.Jr., HanY., ScheneckM.E., BarezS., AdamsA.J.The association between multifocal ERG implicit time delays and adaptation in patients with diabetes.Invest Ophthalmol Vis Sci2007; 48: 5250–6.
47.
KimS.J., SongS.J., YuH.G.Multifocal electroretinogram responses of the clinically normal retinal areas in diabetes.Ophthalmic Res2007; 39: 282–8.
48.
KaracorluM., OzdemirH., SenturkF., Arf KaracorluS., UysalO.Macular function by multifocal electroretinogram in diabetic macular edema after intravitreal triamcinolone acetonide injection.Eur J Ophthalmol2008; 18: 601–8.
